Published online before print July 25, 2005, doi: 10.1161/CIRCULATIONAHA.104.529248
(Circulation. 2005;112:737-744.)
© 2005 American Heart Association, Inc.
Stroke |
Cerebral Vascular Dysfunction in Methionine Synthase–Deficient Mice
From the Departments of Internal Medicine (S.D., A.M.D., R.B.M., F.M.F., S.R.L.) and Pharmacology (F.M.F.), University of Iowa, Carver College of Medicine, Iowa City; Baylor Institute of Metabolic Disease, Dallas, Tex (E.A., T.B.); Department of Nutritional Sciences and Toxicology, University of California–Berkeley (M.-L.L., B.S.); and Veterans Affairs Medical Center, Iowa City, Iowa (S.R.L.).
Correspondence to Steven R. Lentz, MD, PhD, Department of Internal Medicine, C32 GH, University of Iowa, Iowa City, IA 52242. E-mail steven-lentz{at}uiowa.edu
Received December 12, 2004; revision received April 28, 2005; accepted May 6, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Methionine synthase (MS) catalyzes the folate-dependent remethylation of homocysteine to methionine. We tested the hypothesis that deficiency of MS impairs endothelial function in mice heterozygous for disruption of the Mtr gene, which encodes MS.
Methods and Results— Plasma total homocysteine was similar in wild-type (Mtr+/+) and heterozygous (Mtr+/–) mice fed a control diet (4.5±0.3 and 5.3±0.4 µmol/L, respectively) and mildly elevated in Mtr+/+ and Mtr+/– mice fed a low-folate (LF) diet (7.5±0.7 and 9.6±1.2 µmol/L, respectively; P<0.001 versus control diet). Dilatation of cerebral arterioles to the endothelium-dependent dilator, acetylcholine (10 µmol/L) was blunted in Mtr+/– mice compared with Mtr+/+ mice fed the control diet (21±4 versus 32±4%; P<0.05). Both Mtr+/+ and Mtr+/– mice exhibited impaired dilatation of cerebral arterioles to acetylcholine when they were fed the LF diet (12±2 and 14±2%, respectively; P<0.01 versus Mtr+/+ mice fed the control diet). Elevated levels of superoxide and hydrogen peroxide were detected by confocal microscopy in cerebral arterioles of Mtr+/– mice fed the control diet and in both Mtr+/+ and Mtr+/– mice fed the LF diet.
Conclusions— These findings demonstrate that defective homocysteine remethylation caused by deficiency of either MS or folate produces oxidative stress and endothelial dysfunction in the cerebral microcirculation of mice.
Key Words: cerebrovascular circulation • endothelium • homocysteine • superoxides
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Hyperhomocysteinemia, or elevation of plasma total homocysteine (tHcy), is a risk factor for cardiovascular disease and stroke. A meta-analysis of primary data from several large prospective studies concluded that a 3-µmol/L increase in plasma tHcy is predictive of about a 10% increased risk of myocardial infarction and a 20% increased risk of stroke after adjustment for other known risk factors.1 Elevated tHcy is a strong predictor for incident ischemic stroke in patients with coronary heart disease.2 Hyperhomocysteinemia also has been implicated as a risk factor for venous thrombosis,3,4 Alzheimer disease,5,6 and osteoporosis.7,8
Studies in animals and humans have established that hyperhomocysteinemia causes endothelial dysfunction, with impaired endothelium-dependent dilatation of the aorta and other peripheral vessels.9 The cerebral microcirculation appears to be particularly susceptible to endothelial dysfunction during hyperhomocysteinemia.10,11 A major mechanism of hyperhomocysteinemia-induced endothelial dysfunction, in both cerebral and peripheral blood vessels, is related to decreased bioavailability of endothelium-derived nitric oxide (NO).12 There is strong evidence that elevation of homocysteine is linked to oxidative inactivation of NO, but alternative mechanisms of decreased NO bioavailability during hyperhomocysteinemia also have been proposed.13,14 It is not known whether endothelial dysfunction is caused by homocysteine itself or a related metabolite.
Homocysteine is formed during methyl transfer reactions that use S-adenosylmethionine (SAM) as a methyl donor.15 The metabolic fate of homocysteine in most cells depends on the relative activity of 2 cytoplasmic enzymes: (1) cystathionine ß-synthase (CBS), which catalyzes the first step in the transsulfuration of homocysteine to cysteine, and (2) methionine synthase (MS), a cobalamin (vitamin B12)-dependent enzyme that remethylates homocysteine to form methionine. During the MS reaction, a methyl group from 5-methyltetrahydrofolate (5-MTHF) is first transferred to cobalamin, which serves as an intermediate methyl carrier. The methyl group is subsequently transferred to homocysteine, generating methionine. The tissue distribution of CBS is limited largely to liver, kidney, intestine, pancreas, and brain, whereas MS is widely expressed in most tissues.15 The availability of 5-MTHF for homocysteine remethylation depends on the action of methylenetetrahydrofolate reductase (MTHFR). A common polymorphism in the MTHFR gene, 677C
T, produces impaired MTHFR activity and is associated with hyperhomocysteinemia and increased risk of coronary heart disease and stroke, especially under conditions of low-folate (LF) status.16
Using a murine model of CBS deficiency, we11,17,18 and others19 have found that defective transsulfuration is associated with enhanced susceptibility to diet-induced hyperhomocysteinemia and endothelial dysfunction. Endothelial dysfunction also has been observed in MTHFR-deficient mice, which have an indirect defect in homocysteine remethylation resulting from a relative lack of 5-MTHF.10,20 It is not known, however, whether endothelial dysfunction can be caused by a specific genetic defect in MS-catalyzed homocysteine remethylation.
In the present study, we tested the hypothesis that endothelial dysfunction and oxidative stress occur in mice with a direct defect in homocysteine remethylation caused by a targeted disruption of the Mtr gene, which encodes MS.21 Because homozygous disruption of the Mtr gene produces embryonic lethality,22 we chose to study heterozygous (Mtr+/–) mice fed either a control diet or an LF diet. This approach allowed us to examine the vascular effects of an isolated defect in the remethylation pathway in mice with either normal or deficient folate intake. Our findings indicate that impaired homocysteine remethylation resulting from a deficiency of either MS or folate causes oxidative stress and endothelial dysfunction in the cerebral microcirculation.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mice and Experimental Protocol
Mice heterozygous for disruption of the Mtr gene22 were crossbred to C57BL/6J mice for at least 7 generations, and comparisons were performed between heterozygous (Mtr+/–) and wild type (Mtr+/+) littermates. Genotyping for the wild-type and targeted Mtr alleles was performed by PCR.22 At the time of weaning (3 weeks of age), mice were fed either a control diet (LM-485; Harlan Teklad) or an LF diet (TD 00204; Harlan Teklad). Compared with the control diet, the LF diet contained a lower amount of folic acid (0.2 versus 6.7 mg/kg).10 The LF diet also contained 5.0 g/kg succinyl sulfathiazole to prevent folate production from gastrointestinal bacteria. At 10 to 20 weeks of age, mice were anesthetized with sodium pentobarbital (150 mg/kg IP), and blood was collected by cardiac puncture into EDTA (final concentration, 5 mmol/L). Samples of brain and liver were immediately deproteinized in ice-cold perchloric acid (0.4 mol/L), homogenized, and centrifuged. The supernatant fraction was flash-frozen and stored at –80°C for later analysis of SAM, S-adenosylhomocysteine (SAH), and asymmetric dimethylarginine (ADMA). Additional samples of brain and liver were heated by boiling for 10 minutes in 20 g/L sodium ascorbate, 0.2 mol/L 2-mercaptoethanol, 0.25 mol/L HEPES, and 0.25 mol/L Ches, pH 7.85, and then homogenized and centrifuged. The supernatant fraction was treated with rat serum conjugase at 37°C for 3 hours to hydrolyze folate polyglutamates.23 Samples were then boiled for 5 minutes and centrifuged, and the supernatant fraction was stored at –80°C for later analysis of folate. Frozen sections of cerebral arterioles were prepared for measurement of vascular reactive oxygen species (ROS). The aorta was removed and used immediately for vasomotor studies. The University of Iowa and Veterans Affairs Animal Care and Use committees approved all the experimental protocols.
Vasomotor Responses
Relaxation of aortic rings was measured as described previously.17,18 After removal of loose connective tissue, the proximal aorta was cut into multiple 3- to 4-mm rings and suspended in an organ chamber containing oxygenated Krebs’ buffer maintained at 37°C. Rings were precontracted submaximally using the thromboxane analog U46619, and relaxation dose-response curves were generated by cumulative addition of the endothelium-dependent vasodilator acetylcholine (10–8 to 10–5 mol/L) or the endothelium-independent vasodilator nitroprusside (10–8 to 10–5 mol/L).
Dilatation of cerebral arterioles was measured in vivo as described previously.10,11,24 Briefly, mice were anesthetized with sodium pentobarbital and ventilated mechanically with room air and supplemental oxygen. A cranial window was made over the left parietal cortex, and a segment of a randomly selected pial arteriole (
30 µm in diameter) was exposed. The diameter of the arteriole was measured with a video microscope coupled to an image-shearing device under control conditions and during superfusion with acetylcholine (1 and 10 µmol/L) and nitroprusside (0.1 and 1 µmol/L).
Detection of Vascular ROS
The oxidative fluorescent dyes dihydroethidium (DHE) and 5,6-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate acetyl ester (DCF) (both from Molecular Probes, Inc) were used to detect superoxide and peroxide, respectively, in sections of cerebral arterioles as described previously.11,25 Frozen transverse sections (10 µm) of cerebral arterioles were preincubated with PBS, 250 U/mL polyethylene glycol-superoxide dismutase (PEG-SOD, Sigma Chemical Co), or 500 U/mL PEG-catalase (Sigma Chemical Co) and then incubated with 10 µmol/L of either DHE or DCF for 30 minutes at room temperature in a dark chamber. Fluorescence was detected by laser–scanning confocal microscopy.11
Metabolite Assays
Plasma tHcy, defined as the total concentration of homocysteine after quantitative reductive cleavage of all disulfide bonds,26 was measured by high-performance liquid chromatography (HPLC) with SBDF (ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate) fluorescence detection.27 Plasma methionine was measured by HPLC coupled to fluorescence detection after precolumn derivatization with o-phthaldialdehyde as described previously.28 Plasma and tissue folate was measured with the Quantaphase II folate radioimmunoassay (Bio-Rad Laboratories). SAM and SAH concentrations in liver and brain were determined by HPLC using UV detection as described previously.29 Plasma and tissue levels of ADMA, symmetric dimethyarginine (SDMA), and L-arginine were determined by HPLC using precolumn derivatization with o-phthaldialdehyde.30
Statistical Analysis
ANOVA, followed by Tukey’s post-hoc test, was used to compare the effects of Mtr genotype, sex, and diet on tHcy, folate, methionine, SAM, SAH, ADMA, SDMA, and L-arginine. Unpaired 2-tailed Student t test was used to compare cerebral vasomotor responses. Responses to vasodilators in aorta were analyzed by 2-way repeated-measures ANOVA with Tukey’s post hoc test for multiple comparisons. Correlation analysis was performed by linear regression, followed by 1-way ANOVA. A value of P=0.05 was used to define statistical significance. Values are reported as mean±SE.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Plasma tHcy, Methionine, and Folate
Plasma levels of tHcy were influenced by both diet (P<0.001) and Mtr genotype (P=0.05) (Figure 1A). As reported previously,22 plasma tHcy was similar in Mtr+/+ and Mtr+/– mice fed the control diet (4.5±0.3 and 5.3±0.4 µmol/L, respectively). The highest levels of plasma tHcy were observed in Mtr+/+ and Mtr+/– mice fed the LF diet, but even these groups of mice had only mild hyperhomocysteinemia (plasma tHcy, 7.5±0.7 and 9.6±1.2 µmol/L, respectively). Because a previous study in Mtr+/– mice found higher levels of tHcy in female than in male mice,22 we performed 3-way ANOVA to compare the effects of diet, genotype, and sex on plasma tHcy. With this method of analysis, the overall effect of sex was not significant (P=0.38). Plasma levels of methionine were similar in Mtr+/+ and Mtr+/– mice and were not affected by diet (Figure 1B). Plasma folate was markedly decreased in both Mtr+/+ and Mtr+/– mice fed the LF diet but was not affected by Mtr genotype (Figure 1C).
|
Tissue Levels of Folate, SAM, and SAH
Levels of folate in the liver were significantly decreased in both Mtr+/+ and Mtr+/– mice fed the LF diet (P<0.001) (Table 1). Methylation capacity in the liver also was significantly influenced by diet, with mice fed the LF diet having lower levels of SAM (P<0.01) and lower SAM-to-SAH ratios (P<0.05) than mice fed the control diet. By Tukey’s multiple comparison analysis, these effects of diet reached significance for Mtr+/– mice but not for Mtr+/+ mice (Table 1). Levels of SAH in liver did not differ significantly between Mtr+/+ and Mtr+/– mice or between the control and LF diets. No significant effects of Mtr genotype or diet were found on folate, SAM, SAH, or SAM-to-SAH ratio in brain, although there was a trend toward lower folate levels in mice fed the LF diet (P=0.08) (Table 2). As observed previously in CBS-deficient and MTHFR-deficient mice,10,18 the SAM-to-SAH ratio was higher in brain (Table 2) than in liver (Table 1).
|
|
Vasomotor Responses
We observed concentration-dependent relaxation of aortic rings to the endothelium-dependent vasodilator acetylcholine and the endothelium-independent vasodilator nitroprusside in all groups of mice (Figure 2). Relaxation responses to acetylcholine were similar in Mtr+/+ and Mtr+/– mice regardless of diet (Figure 2A and 2B). Similarly, no differences in relaxation responses to nitroprusside were observed between Mtr+/+ and Mtr+/– mice or between diets (Figure 2C and 2D).
|
Indicates Mtr+/+ mice (n=15 for control diet, n=11 for LF diet); •, Mtr+/– mice (n=15 for control diet, n=12 for LF diet).To determine the effects of Mtr genotype and diet on vasomotor responses in the cerebral circulation, dilatation of pial arterioles was measured in anesthetized mice in vivo (Figure 3). When mice were fed the control diet, dose-dependent dilatation to 1.0 and 10 µmol/L acetylcholine was observed in both Mtr+/+ and Mtr+/– mice, but dilatation to 10 µmol/L acetylcholine was blunted in Mtr+/– mice compared with Mtr+/+ mice (P<0.05; Figure 3A and 3B). When mice were fed the LF diet, both Mtr+/+ and Mtr+/– mice exhibited impaired dilatation responses to 10 µmol/L acetylcholine (P<0.05; Figure 3A and 3B). Dose-dependent dilatation of cerebral arterioles in response to nitroprusside was not affected by either diet or Mtr genotype (Figure 3C and 3D).
|
Vascular ROS
Superoxide was detected by laser–scanning confocal microscopy in sections of cerebral arterioles using the oxidative fluorescent dye DHE. As expected, DHE fluorescence was localized to nuclei because of the high affinity of oxidized DHE for nucleic acids (Figure 4).31 Compared with Mtr+/+ mice fed the control diet (Figure 4A), higher levels of microvascular DHE fluorescence were observed in Mtr+/– mice fed the control diet (Figure 4B) and in both Mtr+/+ and Mtr+/– mice fed the LF diet (Figure 4C and 4D). DHE fluorescence in Mtr+/– mice fed the LF diet was strongly inhibited by PEG-SOD (Figure 4E), which suggests that superoxide was the major cause of enhanced DHE fluorescence in this model.
|
Staining with DCF, which detects peroxides and other ROS,31 was elevated in Mtr+/– mice (Figure 5B and 5D) compared with Mtr+/+ mice (Figure 5A and 5C) fed either the control or LF diets. Most of the enhanced DCF fluorescence in Mtr+/– mice fed the LF diet was inhibited by PEG-catalase (Figure 5E), which suggests that enhanced DCF fluorescence in these mice was mediated largely by hydrogen peroxide. A background signal caused by autofluorescence of the elastic lamina was observed in all sections.
|
ADMA
Previous studies have suggested that hyperhomocysteinemia-induced endothelial dysfunction may be mediated by elevation of ADMA, an endogenous inhibitor of NO synthases.32,33 We found that plasma levels ADMA were similar in Mtr+/+ and Mtr+/– mice fed either the control diet or the LF diet (Table 3), although there was a nonsignificant trend toward higher levels of ADMA in mice fed the LF diet compared with mice fed the control diet (P=0.06). There were no significant effects of Mtr genotype or diet on plasma SDMA, L-arginine, or ratio of L-arginine to ADMA (Table 3). Levels of ADMA in the liver did not differ between Mtr+/+ and Mtr+/– mice fed either the control diet (44.9±8.3 versus 50.0±1.0 nmol/g; P=0.51) or the LF diet (34.5±3.4 versus 47.2±7.3 nmol/g; P=0.13). A positive correlation was found between plasma ADMA and liver ADMA (R=0.48, P=0.05).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this study, we used genetic and dietary approaches to determine the effects of altered homocysteine remethylation on vascular oxidative stress and endothelial function in mice. One major finding of our study is that the LF diet produced elevation of plasma tHcy, impaired endothelium-dependent dilatation of cerebral arterioles, and increased vascular ROS in both Mtr+/+ and Mtr+/– mice. These results confirm and extend previous observations implicating diet-induced hyperhomocysteinemia as a mediator of oxidative stress and vascular dysfunction in the cerebral circulation.10,11 A second major finding is that heterozygous deficiency of the Mtr gene in Mtr+/– mice fed the control diet did not alter plasma tHcy but did elicit endothelial dysfunction and increased production of ROS in cerebral arterioles. These observations provide direct evidence that impaired homocysteine remethylation causes oxidative stress and endothelial dysfunction in the cerebral microcirculation of mice, even in the absence of hyperhomocysteinemia.
In agreement with previous studies,10,17 we found that the LF diet produced a highly significant (P<0.001) elevation of plasma tHcy in both Mtr+/+and Mtr+/– mice. The influence of Mtr genotype on plasma tHcy was less ±substantial, with minimal elevation of plasma tHcy seen in Mtr+/– mice fed the control diet (P=0.05) (Figure 1). The modest effect of the Mtr+/– genotype on plasma tHcy is consistent with previous findings in MS-deficient mice.22 The concentration of tHcy in plasma is strongly determined by its metabolism in the liver,18 which is capable of remethylating homocysteine to methionine through an alternative pathway catalyzed by betaine:homocysteine methyltransferase (BHMT). Therefore, we speculate that increased hepatic BHMT-dependent remethylation may maintain plasma tHcy at relatively normal levels in Mtr+/– mice fed the control diet.
Previous studies have suggested that hyperhomocysteinemia produces endothelial dysfunction through oxidative inactivation of endothelium-derived NO.14,34 Our present results are consistent with these prior studies, because we observed endothelial dysfunction with increased superoxide and/or hydrogen peroxide in cerebral arterioles of Mtr+/+ and Mtr+/– mice fed the LF diet (Figures 4 and 5 
). An interesting new finding from the present study is that, despite the absence of hyperhomocysteinemia, Mtr+/– mice fed the control diet also exhibited endothelial dysfunction and elevated levels of both superoxide and peroxide in cerebral arterioles. We have considered several possible mechanisms to account for these findings.
One possibility is that homocysteine itself is responsible for producing oxidative stress and endothelial dysfunction. Homocysteine can undergo auto-oxidation through its free thiol group, potentially leading to direct inactivation of endothelium-derived NO.34 Homocysteine also may increase oxidative stress indirectly by depleting intracellular glutathione or downregulating antioxidant enzymes such as glutathione peroxidase or by upregulating vascular NAD(P)H oxidase.35 Unlike Mtr+/+ and Mtr+/– mice fed the LF diet, Mtr+/– mice fed the control diet did not have a significant elevation of tHcy in plasma, but we cannot exclude the possibility that homocysteine levels may have been elevated in vascular tissue, which lacks compensatory BHMT activity. It remains possible, therefore, that high levels of homocysteine in cerebral microvessels produce local oxidative stress and endothelial dysfunction in Mtr+/– mice.
Another possibility is that it is not homocysteine but another factor related to folate metabolism that is responsible for cerebral vascular dysfunction. Folates are known to have antioxidant properties, and several clinical intervention studies have demonstrated that treatment with folic acid can improve endothelial function in subjects with hypercholesterolemia or atherosclerosis.36 In some of these studies, the improvement in endothelial function was associated with a decrease in markers of systemic oxidative stress.37 Treatment with high-dose folic acid also improves endothelial function in hyperhomocysteinemic subjects,36 an effect that may be independent of plasma tHcy.38,39 In agreement with these findings in humans, folate deficiency has been shown to cause increased lipid peroxidation and decreased cellular antioxidant activity in rats.40,41
Although Mtr+/+ and Mtr+/– mice have similar plasma levels of total folate (Figure 1), it is conceivable that differences in tissue levels of folate or folate pool distribution may contribute to decreased antioxidant activity in Mtr+/– mice. Deficient MS activity in Mtr+/– mice might be expected to cause buildup of 5-MTHF and depletion of other folates, including those required for thymidylate and purine synthesis. An analogous "methyl folate trap" is responsible for megaloblastic anemia in humans with deficient MS activity resulting from pernicious anemia.42 5-MTHF itself has been shown to be a weak scavenger of superoxide and to enhance NO production from endothelial NO synthase, possibly by improving the redox state of the endothelial NO synthase cofactor tetrahydrobiopterin.43 It is not known, however, whether other forms of folate are more or less potent antioxidants compared with 5-MTHF. Clearly, more work is needed to define the redox effects of various folate metabolites.
To begin to address role of tissue folates in the phenotype of MS-deficient mice, we measured levels of total folate in liver and brain, and we did not detect any significant differences between Mtr+/+ and Mtr+/– mice (Tables 1 and 2). Interestingly, however, levels of folate in brain were >10-fold lower than in liver, and the relative influence of the LF diet on folate level was attenuated in brain compared with liver. These findings suggest that tissue-specific differences in folate uptake and metabolism may modulate the phenotypic response to altered homocysteine remethylation. Because of technical limitations, we were not able to measure the distribution of individual folate metabolites in these tissues, but this remains an important goal of future studies.
We also considered the possibility that altered cellular methylation capacity may have contributed to endothelial dysfunction and oxidative stress. Compared with mice fed the control diet, Mtr+/+ and Mtr+/– mice fed the LF diet had significantly lower SAM-to-SAH ratios in the liver (Table 1). The diminished hepatic methylation capacity of these mice might be expected to alter DNA methylation or the generation of other methylated products. No changes in SAM-to-SAH ratio were observed in the brains of mice fed the LF diet, however, and Mtr+/– mice fed the control diet did not exhibit altered methylation capacity in either liver or brain. We have not yet been able to reliably measure SAM or SAH in vascular tissue, so the potential importance of altered methylation to the vascular phenotype of Mtr+/– mice remains to be investigated.
Another methylation product that may influence vascular function during hyperhomocysteinemia is ADMA.44 ADMA is derived from protein methylation reactions that produce homocysteine as a byproduct, and plasma ADMA is elevated during hyperhomocysteinemia in monkeys and humans.44 The effects of hyperhomocysteinemia on ADMA metabolism may be complex, however. A homocysteine-induced decrease in methylation capacity might result in decreased production of ADMA, but homocysteine also may inhibit the hydrolysis of ADMA by dimethylarginine dimethylaminohydrolase.45 We observed only a small trend toward elevated plasma ADMA in Mtr+/+ and Mtr+/– mice fed the LF diet (Table 3), and hepatic levels of ADMA were not elevated in Mtr+/+ or Mtr+/– mice fed the LF diet.
The observation that responses to acetylcholine in aortic rings were unaffected by Mtr genotype or the LF diet is consistent with previous findings in murine models of mild hyperhomocysteinemia. In CBS-deficient mice, for example, endothelial function in the aorta was relatively normal when the concentration of plasma tHcy was <20 µmol/L but became impaired with higher concentrations of plasma tHcy.17,18 In comparison, endothelial dysfunction in the cerebral microcirculation of CBS-deficient mice occurred with very mild elevation of plasma tHcy (8 to 15 µmol/L).11 A similar relative insensitivity of the aorta compared with smaller vessels such as cerebral arterioles or mesenteric arterioles has been observed in MTHFR-deficient mice.10,20 Our present findings in MS-deficient mice provide additional support for the hypothesis that, compared with large conduit vessels such as the aorta, microvessels are hypersensitive to hyperhomocysteinemia-induced endothelial dysfunction.
In summary, we have demonstrated oxidative stress and endothelial dysfunction in cerebral microvessels of mice with genetic or diet-induced defects in homocysteine remethylation. The occurrence of cerebrovascular dysfunction without hyperhomocysteinemia in Mtr+/– mice fed the control diet may have important implications with regard to the mechanisms of stroke, dementia, and other cerebrovascular diseases that are associated with altered homocysteine metabolism. Our findings also may have implications for the ongoing clinical trials of folic acid supplementation to prevent cardiovascular disease and stroke.46
|
Acknowledgments |
|---|
This work was supported by the Office of Research and Development, Department of Veterans Affairs, National Institutes of Health grants HL-63943, NS-24621, HL-38901, HL-62984, HL-58991, and DK-42033; American Heart Association Postdoctoral Fellowship Award to Sanjana Dayal; and a Bugher Foundation–AHA Award. The MS-deficient mice were originally generated in the laboratory of Dr Lawrence C. Brody at the National Human Genome Research Institute. We thank Cynthia Lynch for technical assistance and Dr Francis Miller for advice about DHE and DCF fluorescence.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288: 2015–2022.
2. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, Brunner D, Behar S, Sela BA. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke. 2003; 34: 632–636.
3. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003; 102: 1363–1366.
4. den Heijer M. Hyperhomocysteinaemia as a risk factor for venous thrombosis: an update of the current evidence. Clin Chem Lab Med. 2003; 41: 1404–1407.[CrossRef][Medline] [Order article via Infotrieve]
5. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998; 55: 1449–1455.
6. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002; 346: 476–483.
7. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der KM, de Jonge R, Lindemans J, de Groot LC, Hofman A, Witteman JC, van Leeuwen JP, Breteler MM, Lips P, Pols HA, Uitterlinden AG. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004; 350: 2033–2041.
8. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, Hannan MT, Cupples LA, Kiel DP. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004; 350: 2042–2049.
9. Lentz SR. Homocysteine and cardiovascular physiology. In: Carmel R, Jacobsen DW, ed. Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press; 2001: 441–450.
10. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Blood. 2004; 103: 2624–2629.
11. Dayal S, Arning E, Bottiglieri T, Böger RH, Sigmund CD, Faraci FM, Lentz SR. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke. 2004; 35: 1957–1962.
12. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia. Vasc Med. 2002; 7: 227–239.
13. Jacobsen DW. Hyperhomocysteinemia and oxidative stress: time for a reality check? Arterioscler Thromb Vasc Biol. 2000; 20: 1182–1184.
14. Faraci FM. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol. 2003; 23: 371–373.
15. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990; 1: 228–237.[CrossRef][Medline] [Order article via Infotrieve]
16. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, for the MTHFR Studies Collaboration Group. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. JAMA. 2002; 288: 2023–2031.
17. Lentz SR, Erger RA, Dayal S, Maeda N, Malinow MR, Heistad DD, Faraci FM. Folate dependence of hyperhomocysteinemia and endothelial dysfunction in cystathionine ß-synthase–deficient mice. Am J Physiol. 2000; 278: H970–H975.
18. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine ß-synthase–deficient mice. Circ Res. 2001; 88: 1203–1209.
19. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Tolliet M, Heyrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000; 106: 483–491.[Medline] [Order article via Infotrieve]
20. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL. Effect of hyperhomocysteinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase–deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 1352–7.
21. Chen LH, Liu ML, Hwang HY, Chen LS, Korenberg J, Shane B. Human methionine synthase: cDNA cloning, gene localization and expression. J Biol Chem. 1997; 272: 3628–3634.
22. Swanson DA, Liu ML, Baker PJ, Garrett L, Stitzel M, Wu J, Harris M, Banerjee R, Shane B, Brody LC. Targeted disruption of the methionine synthase gene in mice. Mol Cell Biol. 2001; 21: 1058–1065.
23. Horne DW. Neither methionine nor nitrous oxide inactivation of methionine synthase affect the concentration of 5,10-methylenetetrahydrofolate in rat liver. J Nutr. 2003; 133: 476–478.
24. Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, Faraci FM. Increased superoxide and vascular dysfunction in CuZnSOD-deficient mice. Circ Res. 2002; 91: 938–944.
25. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998; 82: 1298–1305.
26. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, Jacobsen DW, Brattström L, Wilcken B, Wilcken DEL, Blom HJ, Stabler SP, Allen RH, Selhub J, Rosenberg IH. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol. 2000; 20: 1704–1706.
27. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991; 565: 441–446.[Medline] [Order article via Infotrieve]
28. Bottiglieri T. The effect of storage on rat tissues and human plasma amino acid levels determined by HPLC. Biomed Chromatogr. 1987; 2: 195–196.[CrossRef][Medline] [Order article via Infotrieve]
29. Bottiglieri T. Isocratic high performance liquid chromatography analysis of S-adenosylmethionine and S-adenosylhomocysteine in animal tissues: the effect of exposure to nitrous oxide. Biomed Chromatogr. 1990; 4: 239–241.[CrossRef][Medline] [Order article via Infotrieve]
30. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002; 303: 131–137.[CrossRef][Medline] [Order article via Infotrieve]
31. Münzel T, Afanas’ev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol. 2002; 22: 1761–1768.
32. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000; 20: 1557–1564.
33. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetric dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans. Clin Sci. 2001; 100: 161–167.[Medline] [Order article via Infotrieve]
34. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest. 1996; 98: 5–7.[Medline] [Order article via Infotrieve]
35. Faraci FM, Lentz SR Hyperhomocysteinemia, oxidative stress, and cerebral vascular dysfunction. Stroke. 2004; 35: 345–347.
36. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002; 22: 6–13.
37. Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, Banga JD, Rabelink TJ. Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2000; 20: 185–188.
38. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inemia: restoration by folic acid. Clin Sci. 1999; 96: 235–239.[Medline] [Order article via Infotrieve]
39. De Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LA, Van de Voorde J, Lameire NH. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation. 2004; 109: 2331–2336.
40. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis. 1996; 121: 231–243.[CrossRef][Medline] [Order article via Infotrieve]
41. Huang RF, Hsu YC, Lin HL, Yang FL. Folate depletion and elevated plasma homocysteine promote oxidative stress in rat livers. J Nutr. 2001; 131: 33–38.
42. Shane B, Stokstad EL. Vitamin B12-folate interrelationships. Annu Rev Nutr. 1985; 5: 115–141.[CrossRef][Medline] [Order article via Infotrieve]
43. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R, Rabelink TJ. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000; 86: 1129–1134.
44. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosclerosis Suppl. 2003; 4: 61–65.[Medline] [Order article via Infotrieve]
45. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001; 104: 2569–2575.
46. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost. 2000; 26: 341–348.[CrossRef][Medline] [Order article via Infotrieve]
 |
|
 |
|
  K. T. Williams, T. A. Garrow, and K. L. Schalinske Type I Diabetes Leads to Tissue-Specific DNA Hypomethylation in Male Rats J. Nutr., November 1, 2008; 138(11): 2064 - 2069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kitami, R. Rubio, W. O'Brien, J. Quackenbush, and J. H. Nadeau Gene-environment interactions reveal a homeostatic role for cholesterol metabolism during dietary folate perturbation in mice Physiol Genomics, October 8, 2008; 35(2): 182 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dayal and S. R. Lentz Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1596 - 1605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Devlin, R. Singh, R. E. Wade, S. M. Innis, T. Bottiglieri, and S. R. Lentz Hypermethylation of Fads2 and Altered Hepatic Fatty Acid and Phospholipid Metabolism in Mice with Hyperhomocysteinemia J. Biol. Chem., December 21, 2007; 282(51): 37082 - 37090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Narayanasamy, B. Subramaniam, C. Karunakaran, P. Ranganathan, R. Sivaramakrishnan, T. Sharma, V. S. Badrinath, and J. Roy Hyperhomocysteinemia and Low Methionine Stress Are Risk Factors for Central Retinal Venous Occlusion in an Indian Population Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1441 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Colgan and R. C. Austin Homocysteinylation of Metallothionein Impairs Intracellular Redox Homeostasis: The Enemy Within! Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 8 - 11. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dayal, K. M. Wilson, L. Leo, E. Arning, T. Bottiglieri, and S. R. Lentz Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia Blood, October 1, 2006; 108(7): 2237 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Faraci Hydrogen peroxide: watery fuel for change in vascular biology. Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 1931 - 1933. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||